News

Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...

This is the 17th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...

THE INSTAGRAM POST, precision-guided by sex and age, had zeroed in on its target. Yuchen Tu is a conser­vatory-trained viola...

This is the 16th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring...

By Aleszu Bajak, MIT Technology Review | 08.12.2016
Untitled Document

When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was...

By Stephanie Kirchgaessner, The Guardian | 08.12.2016
Untitled Document

There is something like gold flowing through the veins of 100-year-old Maria Tegas, and everyone wants a piece...

By Xavier Symons, BioEdge | 08.11.2016
Untitled Document

Australian bioethicist Rob Sparrow has written extensively on topics ranging from political philosophy and minority rights to the...

By Ian Johnston, The Independent | 08.11.2016
Untitled Document

When scientists announced in 2003 they had used a pioneering technique for the first time to create so-called...

By Lizzie Crocker & Abby Haglage, The Daily Beast | 08.10.2016
Untitled Document

In a November episode of The Mindy Project, a pajama-clad Dr. Lahiri told an auditorium of bright-eyed...

By Whet Moser, Chicago Magazine | 08.09.2016
Untitled Document

In June, 4.1 petabytes of cancer data went online on a new platform, run by the University of...

By Abby Goodnough, The New York Times | 08.09.2016
Untitled Document

TUSCALOOSA, Ala. — Roslyn Lewis was at work at a dollar store here, pushing a heavy cart of...

By Damian Garde, STAT | 08.08.2016
Untitled Document

A biotech company called Seres Therapeutics got some bad news late last month: Its all-important infectious disease drug ...